Lesioni a cellule colonnari CON atipie (FEA/DIN1A) Lesioni a rischio evolutivo? Escissione sempre? SI ?

Slides:



Advertisements
Similar presentations
Endometrial polyps Dr Shaun Monagle MBBS 1991.
Advertisements

Le lesioni colonnari Anna Sapino Università di Torino.
Atypical ductal hyperplasia “A diagnosis of ADH should not be made unless a diagnosis of low grade DCIS is being seriously considered” WHO Breast 2012.
ERCK5/6 Flat epithelial atypia Columnar cell lesions:  A spectrum: columnar cell change, columnar cell hyperplasia, flat epithelial atypia FEA has.
Interventional Radiology : Useful for All and Always ?
Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.
Histopathology and Cytology for Breast lesions Britt-Marie Ljung MD Professor of Pathology, Dir. of Cytology University of California at San Francisco.
MICROCALCIFICATION IN BENIGN BREAST DISEASE
Prostate Cancer Detection in Men with an Initial Diagnosis of Atypical small Acinar Proliferations Dr Charles Chabert The Wollongong Hospital.
A re-audit of Prostate biopsies from January to December 2010 and Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees.
Slide Seminar Sami Shousha, MD, FRCPath Department of Histopathology, Charing Cross Hospital & Imperial College, London Amman, November 2013.
Malignant Adenomyoepithelioma of the Breast with Lymph Node Metastasis
Pathology Journal Reading
High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.
Breast Imaging Made Brief and Simple
Faculty of Medicine - Benha University
Tissue Sampling Options Lisa A. Newman, M.D., M.P.H., F.A.C.S. Professor of Surgery Director, Breast Care Center University of Michigan Ann Arbor, MI.
Ductal Carcinoma In-Situ (DCIS)
Proliferative Epithelial lesions of the Breast
Dr. Malcolm Hayes BC Cancer Agency Vancouver, Canada
Breast Pathology Seminar CASE PRESENTATION PART 1 Elba Torres Matundan MD FCAP Victor Carlo Vargas MD FCAP.
Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA
How are we doing? Quality in Breast Cancer Care Dr Michelle Goecke Surgical Oncology Network Update October 18, 2014.
TUMOURS OF NASAL CAVITY & PARANASAL SINUSES
Marion C.W. Henry, MD Yale University
The Value of Six Month Interval Imaging Following Benign Radiologic-Pathologic Concordant Minimally Invasive Breast Biopsy Manjoros DT, Collett AE, Alberty-Oller.
Assessment of breast microcalcification with stereotactic guidance using the Spirotome Biopsy Needle. Comparison with other biopsy devices Dr Richard Harries.
Tutorial on Breast Pathology Part I: Ductal and Lobular Neoplasias Thomas J Lawton MD, Director Seattle Breast Pathology Consultants, LLC Seattle, WA.
Jump to first page First pregnancy after age 30 (RR 1.48). BMI >29 (RR 1.48). Being a college graduate, independent of OB-GYN history (RR 1.36). (Collaborative.
Done by Mohammad Binhussein & Mohammad Mini.
Endometrial Carcinoma
Outline Intraductal proliferative lesions
Imaging examinations of breasts
Ductal Carcinoma In Situ Shahla Masood, M.D. Professor of Pathology University of Florida College of Medicine - Jacksonville Chief of Pathology and Laboratory.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
Improvement in Screening Radiologists’ Performance in an Organized Screening Program Nancy A. T. Wadden, MD, FRCPC Gregory Doyle, BSc, MBA Breast Screening.
Breast Pathology Emad Raddaoui, MD, FCAP, FASC
Katie Ludwig FY1.   50, 285 New cases of breast cancer  11, 716 deaths  78% - 10 year survival rates  27% preventable cases  Source:
Ten-year Clinicopathological Review Of Ocular Surface Squamous Neoplasia In An Ophthalmological Center In Mexico City Lucero Pedro-Aguilar, M. D. Alvarez-Melloni.
How will you approach the 35-year old, with a 2x2x2cm, firm, mobile, well-circumscribed non-tender mass on her R breast?
Small....but lethal.
BREAST CANCER: Half a million women later… Amy Miglani M.D September 3, 2004.
Breast Tumors Diagnosed as Papillary Neoplasm by FNAB Dae-Kyum Kim, Sang-Uk Woo, Jeong-Han Kim, Seok-Jin Nam, Yoon-La Choi 1, Young-Lyun Oh 1 and Jung-Hyun.
Practical point There are some situations where atypia is noted, but other factors preclude a diagnosis of FEA, ADH, or DCIS. E.g. Very few cells,
W. Scott Campbell, Ph.D., MBA University of Nebraska Medical Center
Educational case 1 Dr JD Hemming Queen Elizabeth Hospital Gateshead.
Management of thyroid nodule.  Introduction.  Guidelines recommendation.  Thyroid nodule work up.  Medical therapy in thyroid nodule  Thyroid nodule.
BREAST CASES ARC 5, VI PAIRS MEETING HAMMAMET-TUNISIA 27 APRIL 2012 S.Mezghani- boussetta,S.Kechaou*, S.Melliti, M.Gadri, M.Chaabene* Ben Arous, Ariana*,
Columnar Cell Lesions Timothy W. Jacobs, M.D. Department of Pathology Virginia Mason Medical Center Seattle, WA.
Investigations of Breast Cancer -by preetam goswami 8th semester,unit-1.
Application of the breast imaging reporting and data system final assessment system in sonography of palpable breast lesions and reconsideration of the.
Ultrasound breast core needle biopsy
Multistep model of breast cancer progression
Dr. Amit Gupta Associate Professor Dept Of Surgery
Fine-needle aspiration of clinically suspicious palpable breast masses with histopathologic correlation Reshma Ariga, M.D., Kenneth Bloom, M.D., Vijaya.
Dr Amit Gupta Associate Professor Dept Of Surgery
July 2017 Dr Suzannah Yarwood
 [P1]Can you put in the numbers here for specificity and NPV
Columnar cell lesions and atypical ductal hyperplasia
Breast Screening and Risk Assessment
Pathologic Upgrade Rates of High-Risk Breast Lesions on Digital Two-Dimensional vs Tomosynthesis Mammography  Leslie R. Lamb, MD, MSc, Manisha Bahl, MD,
معيارهاي ارزشيابي برنامه ثبت سرطان دانشگاهي ارسال به موقع اطلاعات (هر سه ماه)(2) گردآوري از لحاظ پيدا كردن موارد جديد سرطاني از منابع ذيل: - ثبت.
Evaluation of the Real-Q BRAF V600E Detection Assay in Fine-Needle Aspiration Samples of Thyroid Nodules  Kyung Sun Park, Young L. Oh, Chang-Seok Ki,
Nat. Rev. Urol. doi: /nrurol
Low grade intraductal proliferations: ADH vs DCIS
Pathologic Upgrade Rates of High-Risk Breast Lesions on Digital Two-Dimensional vs Tomosynthesis Mammography  Leslie R. Lamb, MD, MSc, Manisha Bahl, MD,
Handling and Evaluation of Breast Cancer Biopsy
AGC&AIS Setareh Akhavan M.D Gynecologist Oncologist
SH-sheikhhasani Gyn-oncologist
Marion C.W. Henry, MD Yale University
Presentation transcript:

Lesioni a cellule colonnari CON atipie (FEA/DIN1A) Lesioni a rischio evolutivo? Escissione sempre? SI ?

The limited available data suggest that when atypia is encountered in a core needle biopsy specimen, subsequent excision shows a more advanced lesion in about 1/3 of cases. This is sufficiently frequent to recommend excision in such cases as a matter of routine Breast Cancer Res 2003; 5: Clinical problems: to excise or not to excise CCC?

Margin evaluation: CCL with atypia should not be taken into consideration even when they are composed of cells that are cytologically similar to those in the diagnostic areas of clinging DCIS. Advances in Anatomic Pathology 2003; 10:

FEA/ADH/CDIS/DIN??????????????????????????????

Virchows Arch (2007) 451:883–891 The term “flat” refers to the overall architecture of the proliferation, which lacks any intraluminal protrusions in the form of arcades, bridges, or micropapillae and is essential in distinguishing this lesion from ADH.

ADH DIN1B FEA DIN1A

Modern Pathology (2009) 1–8

Histology at surgery RX-FU (months) N° Benign Atypia (LIN/ADH/FEA) Mal (DCIS/IC) mean 38 ± 6.8 B2 CCL without atypia685(7%)63 (93%) B3 FEA3813 (34%)20 (53%)5 (13%) CCL without atypia and Papilloma 11 (100%) CCL without atypia or FEA with LIN 112 (18%)5 (45%)1 (9%)3 (27%) CCL without atypia or FEA with ADH 21 (50%) B4 Extensive FEA31 (33%)2 (67%)

2. Multidisciplinary approach for FEA managing 3. Surgery recommended when CCL without atypia or FEA are associated with other risk lesions (ADH/LIN) on VACB; 4. Excision biopsy not mandatory only when histopathological findings are concordant with the radiological features and flat epithelial atypia is found on VACB as the most advanced lesion. Management CCL/FEA 1. CCL without atypia BENIGN

FOLLOW UP?

close followup is advised with repeat mammogram every 6 months for 2–3 years for early detection of any such invasive carcinomas in the vicinity of flat DIN 1. Virchows Arch (2007) 451:883–891

1. Multidisciplinary approach 2. Surgery recommended when CCL without atypia or FEA are associated with other risk lesions (ADH/LIN) on VACB; 3. Excision biopsy not mandatory only when histopathological findings are concordant with the radiological features and flat epithelial atypia is found on VACB as the most advanced lesion. 4. women should be advised of the possible hormone dependency of CCLs. Management CCL/FEA

3D reconstruction of an atypical cystic lobule ER(red) and Ki67(green) in CCL

Laboratory Investigation (2008) 88, 938–948

CCL Not CCL